Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Gattex (teduglutide) is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adult and pediatric patients aged 1 year and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. It enhances intestinal absorption by promoting mucosal growth and improving the structural and functional integrity of the remaining intestine. By mimicking the effects of endogenous GLP-2, Gattex facilitates reduced reliance on parenteral nutrition or intravenous fluids in patients with SBS.
Fact Table | |
Formula | C165H261N47O46 |
License | US FDA (2012) |
Bioavailability | Subcutaneous: ~100% |
Legal status | Prescription only |
Chemical Name | Teduglutide |
Elimination half-life | 1.1 to 2 hours |
Dosage (Strength) | 5 mg per vial for subcutaneous injection |
Pregnancy | Category B – No risk in animal studies |
Brands | Gattex |
Protein binding | Low (peptide hormone) |
PubChem CID | 10072373 |
MedlinePlus | a613028 |
ChEBI | 85041 |
ATC code | A16AX08 |
DrugBank | DB08902 |
KEGG | D09928 |
Routes of administration | Subcutaneous |
Gattex is administered by subcutaneous injection once daily. The recommended dose for both adults and pediatric patients is 0.05 mg/kg body weight per day. It should be injected in the abdomen, thighs, or arms, with rotation of injection sites to prevent local reactions. Gattex must be reconstituted prior to use and should be prepared using aseptic technique. Therapy should be supervised by healthcare professionals experienced in managing patients with SBS.
Active ingredient: teduglutide Inactive ingredients (after reconstitution): mannitol, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, and water for injection (in the diluent). The product is supplied as a lyophilized powder requiring reconstitution.
Gattex is contraindicated in patients with:
Patients should be monitored for gastrointestinal polyps via colonoscopy before starting treatment and periodically thereafter, due to the risk of intestinal neoplasia. Use with caution in patients with a history of malignancies or in those at risk for intestinal obstruction. Monitoring is required for fluid overload, especially in patients with cardiovascular disease or renal impairment. Adjustments in parenteral nutrition should be guided by frequent clinical and laboratory assessments.
Common side effects may include:
Serious adverse events may include intestinal obstruction, biliary and pancreatic disease, and potential for accelerated growth of pre-existing neoplasia.